跳至主要内容
临床试验/NCT02175238
NCT02175238撤回1 期

Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects

Boehringer Ingelheim1 个研究点 分布在 1 个国家开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
撤回
试验地点
1
主要终点
Area under the concentration-time curve of the analyte in plasma and whole blood over the time interval from 0 to the last quantifiable data point (AUC0-tz)

研究概览

简要总结

The primary objective of this trial is to investigate the relative bioavailability and pharmacokinetics in plasma and whole blood of BI 691751 administered as a single dose with and without food in healthy male subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

BI 691751 after high fat breakfast

Experimental

single dose BI 691751 after a standardised high fat breakfast

干预措施: BI 691751 after high fat breakfast (Drug)

BI 691751 fasted

Active Comparator

single dose BI 691751 in fasted state

干预措施: BI 691751 fasted (Drug)

结局指标

主要结局

Area under the concentration-time curve of the analyte in plasma and whole blood over the time interval from 0 to the last quantifiable data point (AUC0-tz)

时间窗: up to 480 hours

Maximum measured concentration of the analyte in plasma and whole blood (Cmax)

时间窗: up to 480 hours

次要结局

  • Area under the concentration-time curve of the analyte in plasma and whole blood over the time interval from 0 extrapolated to infinity (AUC0-inf)(up to 480 hours)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Relative Bioavailability of BI 691751 Administered... | 临床试验